Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Larazotide acetate reduces symptoms in celiac patients undergoing a gluten challenge

A study published ahead of print in the Alimentary Pharmacology & Therapeutics examines larazotide acetate in patients with celiac disease undergoing a gluten challenge.

News image

Celiac disease, an autoimmune disorder triggered by gluten ingestion, is managed by a gluten-free diet, which is difficult for many patients.

Larazotide acetate is a first-in-class oral peptide that prevents tight junction opening, and may reduce gluten uptake and associated sequelae.
 
Dr Kelly and colleagues from Massachussetts, USA evaluated the efficacy and tolerability of larazotide acetate during gluten challenge.
 
The research team performed an exploratory, double-blind, randomized, placebo-controlled study including 184 patients who maintained a gluten-free diet before and during the study.

After a gluten-free diet run-in, patients were randomized to larazotide acetate or placebo, and received 2.7 grams of gluten daily for 6 weeks.

Larazotide acetate 1-mg limited gluten-induced symptoms
Alimentary Pharmacology & Therapeutics

The researchers' outcomes included an experimental biomarker of intestinal permeability, the lactulose-to-mannitol ratio and clinical symptoms assessed by Gastrointestinal Symptom Rating Scale, and anti-transglutaminase antibody levels.
 
The research team observed no significant differences in lactulose-to-mannitol ratios between larazotide acetate and placebo groups.

Larazotide acetate 1-mg limited gluten-induced symptoms measured by Gastrointestinal Symptom Rating Scale.

Mean ratio of anti-tissue transglutaminase IgA levels over baseline was 19 in the placebo group compared with 6, 4 and 8 in the larazotide acetate 1-, 4-, and 8-mg groups, respectively.

The team found that the adverse event rates were similar between larazotide acetate and placebo groups.
 
Dr Kelly and colleagues commented, "Larazotide acetate reduced gluten-induced immune reactivity and symptoms in patients with celiac disease undergoing gluten challenge and was generally well tolerated."

"However, no significant difference in lactulose-to-mannitol ratios between larazotide acetate and placebo was observed."

"Results and design of this exploratory study can inform the design of future studies of pharmacological interventions in patients with celiac disease."

Aliment Pharmacol Ther 2012: DOI: 10.1111/apt.12147
28 November 2012

Go to top of page Email this page Email this page to a colleague

 25 April 2014

Advanced search
 25 April 2014 
Histologic scoring system for alcoholic hepatitis
 25 April 2014 
Genetic factors and viral hepatitis outcomes
 25 April 2014 
Program to train physician extenders for Barrett's endoscopy
 24 April 2014 
Vitamin D levels in adults with Crohn's disease
 24 April 2014 
Gut microbiota in IBS
 24 April 2014 
Imaging liver fat in children
 23 April 2014 
Colorectal cancer risk in MUTYH mutation carriers
 23 April 2014 
Fecal microbiota transplantation therapy
 23 April 2014 
Cancer risk after resection of polypoid dysplasia
 22 April 2014 
Endoscopy guidelines to select patients for colonoscopy
 22 April 2014 
PPI use and cancer in Barrett's
 22 April 2014 
Ledipasvir and sofosbuvir for HCV genotype 1
 17 April 2014 
Screening for low bone mineral density among ulcerative colitis
 17 April 2014 
Diabetes mellitus and acute pancreatitis
 17 April 2014 
Bowel cleansing for colonoscopy
 16 April 2014 
Evaluating pharmacologic agents in IBS
 16 April 2014 
Isotretinoin and IBD risk
 16 April 2014 
Mortality in bleeding Mallory-Weiss syndrome vs peptic ulcer bleeding
 15 April 2014 
Dietary fat and risk of IBD
 15 April 2014 
Quality of life in microscopic colitis
 15 April 2014 
New prognostic score for cirrhosis
 14 April 2014 

5-aminosalicylates in early pregnancy and congenital malformation risk

 14 April 2014 
Changing liver cancer mortality rates in the United States
 14 April 2014 
Inflammatory sacroiliitis by MRI in IBD
 11 April 2014 
H pylori resistance to antibiotics
 11 April 2014 
Predictors of corticosteroid treatment outcomes for ulcerative colitis
 11 April 2014 
Antibiotic combination therapy for ulcerative colitis
 10 April 2014 
Mortality in Crohn's disease
 10 April 2014 
Prophylaxis against venous thromboembolism in hospitalized ulcerative colitis
 10 April 2014 
Probiotic treatment and infant colic
 09 April 2014 
Preventing death in general intensive care
 09 April 2014 
Neoplasm risk after polypectomy
 09 April 2014 
Disclosure program and gastroenterology-related claims
 08 April 2014 

Regurgitation and health-related quality of life in GERD

 08 April 2014 
H. pylori resistance to antibiotics
 08 April 2014 
Management of chronic diarrhea
 07 April 2014 
Gastrointestinal angiodysplastic lesions
 07 April 2014 
Meat intake and liver cancer
 07 April 2014 
Adenoma detection and colorectal cancer risk
 04 April 2014 
Stool DNA tests for colorectal cancer
 04 April 2014 
PET-CT predicts outcome in colorectal liver metastases
 04 April 2014 

Prophylaxis of post-ERCP pancreatitis

 03 April 2014 
Management of esophageal or gastric variceal bleeding
 03 April 2014 
Exclusionary diets for IBD
 03 April 2014 
Mortality with chronic pancreatitis
 02 April 2014 
Disease course of early-onset pediatric IBD
 02 April 2014 
Risk of liver fibrosis progression in chronic hep B
 02 April 2014 
Colorectal cancer and patient survival
 01 April 2014 
Outcomes in patients with Hep C
 01 April 2014 
Diagnosis of functional dyspepsia
 01 April 2014 
Genetic risk factors for stenosis and infections in primary sclerosing cholangitis
 31 March 2014 
Diet-gene interactions and Crohn's
 31 March 2014 
Transjugular intrahepatic portosystemic stent-shunts in Budd–Chiari syndrome
 31 March 2014 
Hepatic decompensation in antiretroviral-treated patients
 28 March 2014 
Glucocorticoids and mortality after colorectal cancer surgery
 28 March 2014 
Long-term metformin use and gastric cancer risk
 28 March 2014 
Distance from a liver transplant center and survival
 27 March 2014 
Radiofrequency ablation vs endoscopy for Barrett's
 27 March 2014 
Omega-3 fatty acid and Crohn's disease
 27 March 2014 
Thromboembolism prophylaxis in IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us